



SCS  
Swiss Chemical  
Society

## Community News

[www.scg.ch](http://www.scg.ch)

[www.chemanager-online.com](http://www.chemanager-online.com)

### SWISS CHEMICAL SOCIETY NEWS

#### SCS MatChem PhD Student Award: Call for Nominations 2025



The Division of Materials Chemistry of the SCS calls for nominations for the 2025 MatChem PhD Student Award.

##### Goal of the Award

Featuring rising stars in the fields of Materials Chemistry.

##### Requirements to apply for the Award

Having defended a PhD in the area of Materials Chemistry within Switzerland between January 2024 and end of May 2025. The same person cannot be nominated twice.

Candidates are nominated by the PhD advisor. The following documents must be submitted: nomination letter from PhD advisor, CV of the candidate and the best first author paper of the thesis. Nominations must be submitted to [matchem@scg.ch](mailto:matchem@scg.ch) by July 15, 2025. Evaluation criteria are the Scientific quality and impact of the published work in the field of Materials Chemistry, Originality of the published work creativity of the study, design or uniqueness of the approaches and concepts employed in the published work and clarity of presentation (in a publication). The evaluation committee are Members of the SCS MatChem board.

The winner as well as all candidates that could not be considered are informed on a personal basis after the evaluation committee meeting (mail and/or letter from the MatChem president). The winner gets a certificate and a prize money of CHF 1'000. The winners are invited to present an invited talk within the MatChem session of the SCS Fall Meeting in Zurich on September 4, 2025. Two winners are anticipated each year, one sponsored by SIKA, one by VIGOR.

Source: <https://scg.ch>

#### Member Meeting DIAC 2025 at at Arxada Visp: Connecting Industrial & Applied Chemistry



This year, the annual DIAC members' meeting took place at Arxada in Visp, providing a dynamic setting for exchange between industry and academia in the field of industrial and applied chemistry. Around 40 participants gathered for a full day of insightful presentations, networking opportunities, and a behind-the-scenes look at one of Switzerland's key specialty chemicals sites.

The meeting began with a welcome coffee, followed by an address from Dr. Olivier Lambrechts, President of Nutrition, Care & Environmental at Arxada, who set the stage for the day.

Dr. Ulrich Mayerhöffer, Head of Technical Evaluation and Development, provided a comprehensive overview of "Arxada's Chemical Network in Visp," highlighting the site's significance and innovative capabilities. Dr. Tanja Schaffer, Global Head BL CDMO at Arxada, then presented on "CDMO @ Arxada – towards customized net-zero solutions," focusing on how Arxada is driving sustainability and tailored solutions in contract development and manufacturing. A key highlight was the DIAC Fellowship Award Ceremony, where Dr. Philippe Dupau (dsm-firmenich Ltd.) was honored for his outstanding contributions to the discovery, development, and industrial implementation of many innovative and robust catalytic methodologies for the sustainable and cost-efficient synthesis of iconic perfumery ingredients. Dr. Dupau delivered a short talk, offering insights into his research and the importance of innovation in the sector. We look forward to his DIAC Fellow lectures at Syngenta in Münchwilen (September 23, 2025), University of Bern (October 8, 2025) and the University of Geneva.

During the official member assembly, the DIAC board saw a transition: Urs Brändli (Dottikon Exclusive Synthesis AG) and Andrea Sting (Sygenta Crop Protection AG) were warmly thanked and bid farewell with deep appreciation for their many years of invaluable contributions to the society's success. Adrian Friedmann (Sygenta Crop Protection AG) and Andreas Müller (Dottikon Exclusive Synthesis AG) were newly elected to the board, bringing fresh ideas and perspectives for the coming years.

After a lunch generously provided by Arxada, participants were given an exclusive plant and lab tour, offering a close-up view of Arxada Visp's broad and advanced production and development capabilities. The 2025 DIAC member meeting at Arxada Visp once again demonstrated the value of exchange and strong connections among chemists within our society.

Source: <https://scg.ch>

#### Prof. Jean-Marc Piveteau Elected as New SCNAT President



The SCNAT Assembly of Delegates elected Jean-Marc Piveteau as President. The mathematician and former Rector of the Zurich University of Applied Sciences will take over the presidency from Philippe Moreillon on July 1, 2025. In addition, David N. Bresch and Othmar Müntener were elected to the Board of Directors.

"The scientific communities expect SCNAT to promote open science that supports networking between scientists from different disciplines. In addition, intensifying the dialog between science and politics and strengthening the anchoring of the natural sciences in society remain key challenges for SCNAT. As President, it is a great responsibility and honor to contribute to meeting these expectations," says Jean-Marc Piveteau.

Piveteau studied mathematics at ETH Zurich. After holding management positions in the private sector, Piveteau became

Professor of Internet Technology at the Rapperswil University of Applied Sciences in 2001 and Rector of the Zurich University of Applied Sciences in 2011. Piveteau, who retired at the beginning of 2025, is a proven leader with an excellent network in the Swiss research and education landscape and in politics. He takes over the presidency from Philippe Moreillon, who has strengthened STEM promotion and policy dialog at SCNAT in particular.

Source: <https://scnat.ch>

## The Knowledge Nation of Switzerland Needs the EU Research Programmes



Switzerland, a knowledge nation, is dependent on the EU research programmes. This is confirmed by a broad-based study presented in Bern. Scienceindustries, the Business Association Chemistry Pharma Life Sciences, has commissioned the study to assess the specific impact of limited access to Horizon Europe for Switzerland – thus creating a sound basis for

the political debate on re-association.

“Switzerland is one of the most innovative countries in the world. However, innovation doesn’t flourish on a national go-it-alone basis, but rather requires international exchange,” warns Stephan Mumenthaler, Director of scienceindustries. The study, which was carried out on behalf of scienceindustries, examined the added value that the research programmes of the European Union (EU) create for Switzerland and the effects of Switzerland’s limited participation between 2021 and 2024. For the first time, the study brings together perspectives from universities, start-ups and industrial companies. It shows that the benefits of full association are cross-sectoral and in the national interest.

### *The added value of the EU programmes is clear*

The study makes abstract risks tangible. The authors Barbara Haering and Sandra Wirth interviewed numerous experts and evaluated international impact models. The result is clear: The EU research programmes bring tangible economic, scientific and social benefits for Switzerland. Although the transitional financing between 2021 and 2024 was able to cushion the short-term negative effects, it does not prevent the structural damage.

The RHOMOLO simulation, which is used in the EU to estimate the impact of policy measures, also shows that Horizon Europe can increase EU GDP by up to 0.17% (in 2020 terms), mainly through increased productivity thanks to higher investment in research and development. In doing so, it becomes clear that research investments have a stronger impact if they are pooled across borders rather than remain isolated nationally.

### *Limited participation weakens competitiveness*

These macroeconomic simulations of the EU, the impact model on which the study is based and the estimates of Switzerland’s State Secretariat for Education, Research and Innovation (2019) emphasise that the negative effects of Switzerland’s limited participation in the EU programmes are impacting the competitiveness of the knowledge-based industry as a whole.

As a result of limited access, Switzerland not only lost individual projects, but also its strategic presence along the entire value chain – from research and innovation to market design and regulation. Its interests were less visible, less effective and less involved in the European sphere of science and innovation. And this at a time when global challenges such as climate change or security issues can no longer be solved in a national context. According to the study, young researchers, students and small and medium-sized enterprises in high-tech sectors were particularly

handicapped. It is precisely these target groups of the EU programmes that are relevant for the future of Switzerland.

Erich Rüttsche, Business Development IBM Research, provided a practical perspective at the media conference. He used concrete examples to underline the importance of open collaboration in European programmes for research and development: “Many years of experience show that collaboration in research programs at both European and Swiss level brings concrete positive results for science, business and also society. IBM in Rüschlikon, for example, has produced critical security technologies in the field of quantum-safe encryption, which form the backbone of the IT of the future.”

### *Securing connections with future technologies and digitalisation*

There is still planning and legal uncertainty for researchers and companies regarding the options for participating in EU programmes. This has a particularly negative impact on project submissions from companies.


Switzerland’s full association with the EU programmes is also relevant for Europe’s competitiveness – especially in times of increasing bloc formation and fiercer competition between Europe, Asia and the USA. The exclusion of Switzerland from key high-tech areas such as digitalisation and future technologies such as quantum, semiconductors, space and cyber will ultimately hinder both sides.

### *What’s needed now is political will*

Fundamental innovations are based on long-term research and publicly funded developments. Research and innovation depend on stable framework conditions. The solution is on the table: An association with Horizon Europe is possible – and urgently needed. Switzerland must not miss this opportunity. This is not a technical detail, but a key decision for research, business and location policy. Time is of the essence. Stephan Mumenthaler, Director of scienceindustries, draws a clear conclusion: “The study makes it clear that the knowledge nation of Switzerland is challenged. We need a long-term, stable and well-regulated relationship with the European Union. The Bilaterals III offer a unique opportunity for Switzerland.”

Source: <https://scienceindustries.ch> (with support of the SCS)

## Call for Nominations: Balarew Award 2025



The Subcommittee on Solubility Equilibrium Data (SSED) presents since 2023 the Balarew Award to be awarded to a young scientist working in the areas of solubility and/or homogeneous equilibrium data. Nominations are invited for the Balarew Award for an Outstanding Young Scientist working in the field of solubility and/or related chemical equilibria.

The application can only be made by, at least, one sponsor.

Each nomination should be completed online and accompanied by a letter of support providing a brief statement of the nominee’s achievements, supporting their nomination, including a brief curriculum vitae with a list of recent publications.

The winner must give a research presentation during the International Symposium on Solubility and Related Equilibrium Processes (ISSP21) in Bulgaria in 2026 and a brief description of the awardee’s work will be published in Chemistry International and on the IUPAC website.

Deadline for nominations is June 30, 2025.  
More information: <https://iupac.org>

## A Warm Welcome to Our New Members!



Period: 29.04. – 22.05.2025

Jalal Hasan Mohammed Ali, Karbala (IR) - Benjamin Aymoz, Zurich - Marius Balizs, Villigen - Georges Barnikol, Renens - Anita Berg, Zurich - Bence Botlik, Zurich - Lyna Bourehil, - Jakob Braun, Zurich - Sébastien Bruisson, Fribourg - Luca Bürgi, Lenzburg - Jovanni Cabana, Villigen - Simon Cerqua, Zurich - Oliver Dennis, Chavannes-pres-Renens - Frank Dettner, Basel - Orane Domecq-cazaux, Geneva - Nanchen Dongfang, Zurich - Gabriela Teodora Dutca, Zurich - Amy Fraley, Zurich - Rene Frecot, Zurich - Paul Gärtner, Otelfingen - Alisson Gillon, Fribourg - Lucija Glazer, Zurich - Annick Goergler, Colmar (FR) - Nerea Gonzalez Sanchis, Geneva - Felix Graber, Zurich - Kota Hanasaki, Winterthur - Katarzyna Hanc, Zurich - Rassil Hayder, Zurich - Ida Hipfinger, Zurich - Sophia Hönig, Sankt Augustin (DE) - Zong Xiang Hu, Rümlang - Sarah Jäggi, Zurich - Augustina Jozeliunaite, Thônex - Eunsong Jung, Zurich - Arbias Kadriu, Zuchwil - Dmitry Kalupin, Zurich - Owen Kanisius, Geneva - Anton Kliuchynskyi, Zurich - Julia Lorenzetti, Dübendorf - Haris Majstorovic, Basel - Kaloyan Milanov, Zurich - Eléonore Moore, Zurich - Théo Neukomm, Renens - Nicolas Nötel, Zurich - Paula Oeser, Lausanne - Matilde Piras, Zurich - Md Atiutr Rahman, Dübendorf - David Reber, Dübendorf - Giacomo Renno, Geneva - Stefanie Schiele, Zurich - Kourosh Shariat, Zurich - Samapika Sinha, Basel - Negar Soltani, Zurich - Sara Staudhammer, Wallisellen - Quentin Stucker, Mies - Min Li Tan, Villigen - Congrui Tan, Zurich - Marie Théry, Villigen - Noah von Fellenberg, Zurich - Luca Joey Weigel, Zurich - Fabian Willenborg, Zurich - Xinyue Zhang, Basel.

## HONORS, AWARDS, APPOINTMENTS

### SCS Lectureship Award: Prof. Tehshik P. Yoon, University of Wisconsin-Madison, USA: May 19–23, 2025



The SCS Lectureship is awarded to world-class distinguished scientists and it is organized under the patronage of the Swiss Chemical Society. Over a week, the lecturer gives five presentations and discusses with colleagues at four to five different Swiss research institutions.

Title of Prof. Tehshik's lecture tour was «Stereocontrol in Photochemical Reactions»


Mon, May 19, 2025, 16.30h, University of Zurich  
Y03-G-95, Irchel Campus, Winterthurerstrasse 190, Zürich  
Tue, May 20, 2025, 17:30h, University of Basel  
Small Lecture Hall Organic Chemistry, St. Johannis-Ring 19, Basel  
Wed, May 21, 2025, 16:30h, University of Bern  
Lecture hall EG16, DCBP, Freiestrasse 3, Bern  
Thu, May 22, 2025, 16:15h, EPFL Lausanne  
Génopode, auditorium C, Lausanne-Ecublens  
Fri, May 23, 2025, 14:15h, University of Geneva  
Auditoire A-300, SCII, Quai E. Ansermet 30, 1205, Genève  
Tour organizer: Prof. Olivier Baudoin, University of Basel

The SCS Lectureships Awards are financially supported by Helvetica and the SCNAT and organized by the SCS Division of Fundamental Research DFR.

Source: <https://scg.ch>

## JOURNAL NEWS

### Helvetica, Volume 108, Issue 5, May 2025



HELVETICA  
chimica acta  
WILEY-VCH

#### Review

Approaches to Commercial Sandalwood Odorants from Renewable Sources

Anthony A. Birkbeck, Christian Chapuis, Michel Schalk

#### Research Article

Efficient Polymer Functionalization by Means of Extreme Ultraviolet

Di Qu, Minglei Wang, Léonard Bezingue, Celine Hensky, Filippo Longo, Claudia Masucci, Mirushe Suloska, Jing Wang, Davide Bleiner

Access to Enantioenriched 1,*n*-Diols by Cu-Catalyzed Enantioselective Protoboration and Hydroboration of Alkenyl Ethers

Arthur Flaget, Orlando Cesa, Clément Mazet

Palladium-Catalyzed [3+2+2] Cycloaddition Between Carbonyl-Tethered Alkylidenecyclopropanes and Isocyanates

Ricardo Rodiño, Jose L. Mascareñas, Fernando López

First Report of Hydrolysis of Dihydrazides into Carboxylates in Mild Aqueous Conditions

Kilian Caillaud, Kilian Pouchelon, Fernande Da Cruz-Boisson, Élodie Fromentin, Agnès Crépet, Catherine Ladavière

Electric Dipole Polarizability Calculation for Periodic and Non-Periodic Systems using Atomic-Orbitals-based Linear Response Theory

Ravi Kumar, Sandra Lubet

Understanding the Structure of Protonated Box Ligands: Insights from Spectroscopy and Computational Studies

Vladimir Gorbachev, Lara van Tetering, Jonathan Martens, Jos Oomens, Giel Berden, Alexandra Tsybizova, Peter Chen

How Native Are Peptides After Activation by Collisions or Photons? A Gas-Phase FRET Study

Kim Greis, Linus F. Busse, Lukas R. Benzenberg, Ri Wu, Renato Zenobi

Enhanced Photocatalytic Alkylation using Mg(SPh)<sub>2</sub>: The Role of Lewis Acidity in Catalyst Activity

Yasuhiro Yamashita, Tomoya Hisada, Yuki Sato, Shū Kobayashi

Photocleavable Porphyrin Derivatives for Quantum Optics

Olga Rybakova, Josef Reisinger, Philipp Rieser, Philipp Geyer, Stefan Gerlich, Markus Arndt, Amal Kumar, Daniel Häussinger, Marcel Mayor, Valentin Köhler

## INDUSTRIAL NEWS

Source: [www.chemanager-online.com](http://www.chemanager-online.com)

### From Innovation to Implementation

April 23, 2025: What happens when over 300 pharmaceutical leaders from across Europe and beyond gather in Berlin? Insightful discussions, strategic collaboration and opinions exchange — all under one roof. The 5<sup>th</sup> edition of the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP), held on 14–15 April, brought together decision-makers from across the pharmaceutical value chain to explore the technologies, trends and innovations shaping drug production and packaging. PHARMAP 2025 provided insightful perspectives on the latest trends in pharmaceutical manufacturing, sustainability, automation, and digital transformation. The conference showcased the industry's ongoing innovation and highlighted emerging challenges and solutions shaping the future of pharma. The event welcomed leading global players, including Sandoz, Merck, Novartis, Bayer, Takeda, F. Hoffmann-La Roche, and Almirall S.A., among many others. As the industry navigates a period marked by cost pressures, regulatory evolution, and increasing demand for sustainability and digitalisation, the Congress provided a business programme full of peer-level exchange, insights, and practical solutions. The 5th-anniversary edition was proudly supported by CryoXpert – the medical division of Dohmeyer – as the Principal Sponsor. A longstanding partner of the Congress, CryoXpert was represented by Frans Mortier, Strategic Sales Manager, who delivered a welcome speech during the opening panel. He also participated in a session on efficiency in pharmaceutical manufacturing. His presentation focused on the rapid development of mRNA-based therapies, outlining the operational shifts required to move from clinical trials to commercial launch. Key points included the importance of regulatory alignment, manufacturing scale-up, and supply chain preparedness in supporting the wider adoption of mRNA technologies. The list of speakers in this session also contained: Björn-Thoralf Erxleben, Senior Manager Market Manager Pharma & Biopharma at Shimadzu Europa; Antonella Cimatti, CDMO Strategic Account Manager – Morpho; Giovina Di Meo, Project & Product Lifecycle Management Office Coordinator at Alfasigma; Devendra Ridhurkar, CEO at RidNova Pharmaceuticals.

Sustainability also featured prominently in the PHARMAP 2025 agenda. During the opening panel, Stanislav Kazanov, Head of Sustainability at Innovise, delivered an insightful presentation on digital intelligence in green drug manufacturing. He presented case studies showing how pharmaceutical manufacturers have reduced energy consumption and decreased waste through IoT-based monitoring and AI-driven insights. The presentation included implementation strategies and ROI analysis of successful deployments. The topics of the session also referred to:

- digital transformation of drug manufacturing and packaging – presented by Thierry Marchal, Chief Technologist Healthcare EMEA at Ansys
- strategies for ensuring safe medicines – shown by Chakravarthi AVPS, Global Ambassador at the World Packaging Organisation
- emerging challenges in pharmaceutical manufacturing - delivered by Ayse Hizli, Director of New Business and Global Partnerships Strategy at Sandoz
- evolving dynamics of the global supply chain – illustrated by Ton Knipscheer, Executive Director at ECPA (European Co-Packers Association)

The 5<sup>th</sup> PHARMAP Congress reinforced its role as a dedicated platform for knowledge exchange, strategic alignment, and innovation within pharmaceutical manufacturing and packaging. The next edition of PHARMAP is scheduled for 20–21 April in Amsterdam,

the Netherlands. In 2026, PHARMAP will continue to operate in a closed-door format, fostering a focused and confidential environment for high-level dialogue. The agenda explores how pharmaceutical manufacturers can strike a balance between functionality, safety, and brand integrity, what defines a win-win partnership, and how to take personalised medicine to the next level.

### Hovione and Firstgene Announce Strategic Collaboration

May 9, 2025: An exclusive licensing and R&D collaboration between Hovione and Firstgene aims at accelerating the development of a novel gene vector platform for precision gene therapy in Hepatocellular Carcinoma.

Lisbon, Portugal-based Hovione, an international integrated pharmaceutical development and manufacturing organization, and Mainz, Germany-based Firstgene Life Sciences, a portfolio company of the Swiss incubator Xlife Sciences, announced a strategic collaboration to advance Hovione's proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC), a therapeutic indication developed by Firstgene. Under the terms of the collaboration, Hovione will grant Firstgene an exclusive license to its proprietary novel targeted Adeno-Associated Virus (AAV)-Like particle technology for the treatment of HCC and will provide preclinical R&D services. The virus-like particle technology will be engineered and functionalized for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles, and the execution of proof-of-concept studies. "We are thrilled to see our new gene vector particle platform adopted by Firstgene and its forward-thinking leadership team," said Jean-Luc Herbeaux, Chief Executive Officer of Hovione. "We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level. This partnership is a testament to our mission of turning scientific complexity into real-world solutions that truly make a difference for patients." "Firstgene is proud to highlight its collaboration with Hovione on this groundbreaking project. HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need. The combination of Hovione's expertise in complex chemistry and particle engineering and the commercialization expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options", said Alexander Zink, Managing Director of Firstgene Life Sciences.

### Clariant Denies Dow Europe's Competition Law Allegations in €767 Million Claim

May 12, 2025: Clariant firmly denies Dow Europe's 2020 competition law allegations against four chemical companies. Clariant, a sustainability-focused specialty chemical company, today announced that on 9 May 2025, the company received a claim for damages against four companies, including Clariant, from Dow Europe with the court of Munich, Germany. The claim alleges damages totaling to around €767 million in relation to infringement of competition law on the ethylene purchasing market which was sanctioned by the European Commission in July 2020. Clariant firmly rejects the allegation and will adamantly defend its position in the proceedings. Dow Europe was not a supplier of ethylene to Clariant and Clariant has substantiated economic evidence that the conduct of the parties did not produce any effect on the market.

### Bachem Expands Multi-Site Production Capacities

May 22, 2025: The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK, and Switzerland. Bachem has announced major investments across their site network, with new funding to improve production facil-

ities at their Bubendorf, Vista, and St Helens sites, along with a new site in Sisseln. The expansion plans respond to the growing demand for peptides and oligonucleotides therapeutics. With the global market for obesity drugs expected to increase by more than 15-fold by 2030, Bachem continues to scale operations in line with rising demand.

#### *Stepping up Large-Scale Peptide Production at Bubendorf*

At its Bubendorf site, Bachem is expanding its large-scale operations with a new state-of-the-art production facility known as Building K. The building incorporates high-capacity production cells for scalable synthesis, advanced energy systems (heating, cooling, water, cold storage, etc.), and a specialized tank farm for large-scale operations.

#### *Increased Capacities at Vista Site*

At their Vista site, Bachem has directed funding to increase annual peptide production capacity to nearly one metric ton. New features will include:

- Large-scale SPPS reactors for efficient peptide synthesis.
- Cleavage equipment train with two filter dryers to enhance throughput.
- Increased tank farm & waste management to support high-volume operations.
- Automated glass washer & new heating/chilling systems for operational efficiency.

#### *Increasing Production for Diagnostic Peptides at UK Site & Plans for New Sisseln Site*

Improvements to Bachem's St Helens site infrastructure have resulted in a doubling of output, with a focus on the development of research chemicals. Separately, a new site at Sisseln is being developed in northwestern Switzerland, with concept designs underway.

#### **Siegfried Expands Production Capacity in El Masnou**

May 23, 2025: Siegfried, a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, today announced a further expansion of its ophthalmic drug manufacturing site in El Masnou near Barcelona, Spain. The latest expansion will significantly increase the site's sterile eye drop manufacturing capacity in response to growing customer demand. The new capacity will be available for customers beginning in 2027. This additional expansion complements the company's ongoing initiative to increase production capacity for sterile eye care ointments, which is expected to be available to customers by 2026. It also includes the acquisition of state-of-the-art equipment compliant with the European Union's Annex 1 regulations for the manufacture of sterile medicinal products. Marcel Imwinkelried, CEO commented, "We see continued strong demand for ophthalmic products and the expansion of our El Masnou site will provide valuable additional capacity for our customers. This expansion enhances our global ophthalmic manufacturing footprint and enables us, together with our ophthalmics site in Irvine, US, to effectively serve Europe and the US."



## Innovation that makes an impact

Learn more about our commitment and what we do to **Find, Fight and Follow<sup>®</sup>** disease to deliver better patient outcomes by visiting [Lantheus.com](https://Lantheus.com).



Visit us: [Lantheus.com](https://Lantheus.com)

 @Lantheus
